FRI0128 A NOVEL FORMULATION OF CT-P13 (INFLIXIMAB BIOSIMILAR) FOR SUBCUTANEOUS ADMINISTRATION: 1-YEAR RESULTS FROM A PART 1 OF PHASE I/III RANDOMIZED CONTROLLED TRIAL IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS

Phase I ◽

Controlled Trial ◽

Subcutaneous Administration ◽

SAT0170 A NOVEL FORMULATION OF CT-P13 FOR SUBCUTANEOUS ADMINISTRATION: 30 WEEK RESULTS FROM A PART 2 OF PHASE I/III RANDOMIZED CONTROLLED TRIAL IN PATIENTS WITH RHEUMATOID ARTHRITIS

10.1136/annrheumdis-2019-eular.612 ◽

2019 ◽

Cited By ~ 1

Author(s):

Rene Westhovens ◽

Piotr Wiland ◽

Marek Zawadzki ◽

Delina Ivanova ◽

Alfredo Berrocal ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Phase I ◽

Controlled Trial ◽

Subcutaneous Administration ◽

The Effect of Puerarin on Carotid Intima-media Thickness in Patients With Active Rheumatoid Arthritis: A Randomized Controlled Trial

Clinical Therapeutics ◽

10.1016/j.clinthera.2018.08.014 ◽

2018 ◽

Vol 40 (10) ◽

pp. 1752-1764.e1 ◽

Cited By ~ 3

Author(s):

Min Yang ◽

Yong Luo ◽

Tao Liu ◽

Xiaolong Zhong ◽

Jiao Yan ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Controlled Trial ◽

Intima Media Thickness ◽

Carotid Intima Media Thickness ◽

Randomized Controlled ◽

Media Thickness

Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial

BioDrugs ◽

10.1007/s40259-017-0232-7 ◽

2017 ◽

Vol 31 (4) ◽

pp. 357-367 ◽

Cited By ~ 17

Author(s):

Dae Hyun Yoo ◽

Chang-Hee Suh ◽

Seung Cheol Shim ◽

Slawomir Jeka ◽

Francisco Fidencio Cons Molina ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Phase I ◽

Controlled Trial ◽

Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: Results from a randomized controlled trial

Arthritis & Rheumatism ◽

10.1002/art.30194 ◽

2011 ◽

Vol 63 (3) ◽

pp. 622-632 ◽

Cited By ~ 50

Author(s):

Maria W. Greenwald ◽

William J. Shergy ◽

Jeffrey L. Kaine ◽

Marianne T. Sweetser ◽

Kye Gilder ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Controlled Trial ◽

Tumor Necrosis Factor Inhibitor ◽

Randomized Controlled ◽

Factor Inhibitor ◽

Necrosis Factor

Function and health-related quality of life: Results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis

Arthritis & Rheumatism ◽

10.1002/1529-0131(199909)42:9<1870::aid-anr11>3.0.co;2-d ◽

1999 ◽

Vol 42 (9) ◽

pp. 1870-1878 ◽

Cited By ~ 67

Author(s):

Vibeke Strand ◽

Peter Tugwell ◽

Claire Bombardier ◽

Andreas Maetzel ◽

Bruce Crawford ◽

...

Keyword(s):

Quality Of Life ◽

Rheumatoid Arthritis ◽

Controlled Trial ◽

Health Related Quality ◽

Randomized Controlled ◽

Related Quality ◽

Health Related

Faculty Opinions recommendation of Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.9664956.10337054 ◽

2011 ◽

Author(s):

Ulf Müller-Ladner

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Controlled Trial ◽

Tumor Necrosis Factor Inhibitor ◽

Randomized Controlled ◽

Factor Inhibitor ◽

Necrosis Factor

Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: A randomized, controlled trial

Arthritis & Rheumatism ◽

10.1002/art.20167 ◽

2004 ◽

Vol 50 (2) ◽

pp. 364-371 ◽

Cited By ~ 48

Author(s):

C. Michael Lambert ◽

Sharron Sandhu ◽

Alison Lochhead ◽

Nigel P. Hurst ◽

Euan McRorie ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Dose Escalation ◽

Controlled Trial ◽

Effect of Xinfeng capsule in the treatment of active rheumatoid arthritis: a randomized controlled trial

Journal of Traditional Chinese Medicine ◽

10.1016/s0254-6272(15)30150-3 ◽

2015 ◽

Vol 35 (6) ◽

pp. 626-631 ◽

Cited By ~ 1

Author(s):

Wang Yali ◽

Liu Jian ◽

Wang Yuan ◽

Sun Yue

Keyword(s):

Rheumatoid Arthritis ◽

Controlled Trial ◽

Randomized Controlled ◽

Xinfeng Capsule

Tu2018 - Novel Formulation of CT-P13 (Infliximab Biosimilar) for Subcutaneous Administration: Initial Results from a Phase I Open-Label Randomized Controlled Trial in Patients with Active Crohn's Disease

Gastroenterology ◽

10.1016/s0016-5085(18)34477-9 ◽

2018 ◽

Vol 154 (6) ◽

pp. S-1371 ◽

Cited By ~ 3

Author(s):

Stefan Schreiber ◽

Byung Ik Jang ◽

Vladimir Borzan ◽

Adi Lahat ◽

Aldis Pukitis ◽

...

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Phase I ◽

Controlled Trial ◽

Subcutaneous Administration ◽

Open Label ◽

Randomized Controlled ◽

Initial Results

Impact of yoga based mind-body intervention on systemic inflammatory markers and co-morbid depression in active Rheumatoid arthritis patients: A randomized controlled trial

Restorative Neurology and Neuroscience ◽

10.3233/rnn-180875 ◽

2019 ◽

Vol 37 (1) ◽

pp. 41-59 ◽

Cited By ~ 7

Author(s):

Surabhi Gautam ◽

Madhuri Tolahunase ◽

Uma Kumar ◽

Rima Dada

Keyword(s):

Rheumatoid Arthritis ◽

Inflammatory Markers ◽

Controlled Trial ◽